LONA (LeonaBio) Total Liabilities: $22.29 Mil (As of Mar. 2026)


LONA LeonaBio Inc LONA
28 GF Score
Price $8.80
! 2 Warning Signs
View Full Analysis

What is LeonaBio Total Liabilities?

LeonaBio LONA -0.79% 28 Total Liabilities is $22.29 Mil as of Mar. 2026. GuruFocus rates LONA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

LeonaBio's Total Liabilities for the quarter that ended in Mar. 2026 was $22.29 Mil.

LeonaBio's quarterly Total Liabilities increased from Sep. 2025 ($3.25 Mil) to Dec. 2025 ($64.36 Mil) but then declined from Dec. 2025 ($64.36 Mil) to Mar. 2026 ($22.29 Mil).

LeonaBio's annual Total Liabilities declined from Dec. 2023 ($30.06 Mil) to Dec. 2024 ($13.94 Mil) but then increased from Dec. 2024 ($13.94 Mil) to Dec. 2025 ($64.36 Mil).

LeonaBio Total Liabilities Historical Data

* Premium members only.

The historical data trend for LeonaBio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LeonaBio Total Liabilities Chart

LeonaBio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 10.92 23.02 30.06 13.94 64.36

LeonaBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.18 3.56 3.25 64.36 22.29
LONA
28GF Score
LeonaBio Inc LONA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LeonaBio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LeonaBio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=47.503+(0.338+16.52
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=64.36

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=92.151-27.79
=64.36

LeonaBio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.666+(0.213+15.408
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=22.29

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=71.59-49.303
=22.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $22.29 Mil mean?
LeonaBio (LONA) has a Total Liabilities of $22.29 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LeonaBio and its competitors.
Is LeonaBio's Total Liabilities too high?
LeonaBio's current Total Liabilities is $22.29 Mil. Overall, LeonaBio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does LeonaBio's Total Liabilities compare to ICCC and TELO?
LeonaBio's Total Liabilities of $22.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LeonaBio and its competitors. LeonaBio's current Total Liabilities is $22.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeonaBio stock overvalued right now?
LeonaBio (LONA) has a current Total Liabilities of $22.29 Mil. The current Total Liabilities is $22.29 Mil. LeonaBio's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For LeonaBio (LONA), the current Total Liabilities is $22.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LeonaBio Business Description

Address 18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
28GF Score

Get the complete analysis for LONA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.80
Price